Enanta Pharmaceuticals Inc (ENTA) — Cash Flow-to-Debt Ratio
Enanta Pharmaceuticals Inc (ENTA) has a Cash Flow-to-Debt Ratio of -0.06x as of December 2025, meaning its operating cash flow of $-11.70 Million could theoretically repay 0% of its total liabilities ($202.91 Million) in one year. See how much free cash does Enanta Pharmaceuticals Inc generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Enanta Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Enanta Pharmaceuticals Inc across 15 annual periods. Also explore net asset growth rate of Enanta Pharmaceuticals Inc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Enanta Pharmaceuticals Inc (2011–2025)
Year-by-year debt coverage analysis for Enanta Pharmaceuticals Inc. For market capitalisation and broader financial context, see market value of Enanta Pharmaceuticals Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.09x | $-19.27 Million | $216.01 Million | ▲ +71.9% |
| 2024 | -0.32x | $-78.76 Million | $247.84 Million | ▲ +24.4% |
| 2023 | -0.42x | $-103.15 Million | $245.54 Million | ▲ +70.6% |
| 2022 | -1.43x | $-84.78 Million | $59.26 Million | ▲ +15.3% |
| 2021 | -1.69x | $-70.00 Million | $41.43 Million | ▼ -939.2% |
| 2020 | 0.20x | $7.09 Million | $35.21 Million | ▼ -92.3% |
| 2019 | 2.61x | $71.42 Million | $27.34 Million | ▲ +83.7% |
| 2018 | 1.42x | $29.22 Million | $20.55 Million | ▼ -32.6% |
| 2017 | 2.11x | $52.65 Million | $24.96 Million | ▼ -33.2% |
| 2016 | 3.16x | $35.81 Million | $11.34 Million | ▼ -59.4% |
| 2015 | 7.78x | $76.67 Million | $9.86 Million | ▲ +160.6% |
| 2014 | 2.98x | $20.18 Million | $6.76 Million | ▲ +82.2% |
| 2013 | 1.64x | $10.65 Million | $6.50 Million | ▼ -40.4% |
| 2012 | 2.75x | $22.62 Million | $8.23 Million | ▲ +1708.2% |
| 2011 | 0.15x | $24.02 Million | $158.06 Million | — |